{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Hologic, Inc. Experiences Valuation Adjustment Amid Competitive Market Landscape
Hologic, Inc. has recently adjusted its valuation, with a current P/E ratio of 21 and a Price to Book Value of 3.71. The company demonstrates solid profitability through metrics like a 17.31% ROCE and a 17.54% ROE, while its valuation metrics vary compared to peers in the sector.
Is Hologic, Inc. overvalued or undervalued?
As of October 17, 2025, Hologic, Inc. is fairly valued with a P/E ratio of 21, an EV to EBITDA of 14.41, and a PEG ratio of 1.65, positioning it competitively against peers, despite underperforming the S&P 500 over the past year.
Is Hologic, Inc. technically bullish or bearish?
As of August 29, 2025, Hologic, Inc. shows a mildly bullish technical trend with mixed signals across time frames, but its underperformance relative to the S&P 500 raises concerns about its long-term outlook.
Is Hologic, Inc. overvalued or undervalued?
As of February 5, 2025, Hologic, Inc. is fairly valued with a P/E ratio of 21 and has underperformed the S&P 500, showing a year-to-date return of -5.30% compared to the index's 12.22% gain.
Hologic, Inc. Hits Day High with 7.69% Surge in Stock Price
Hologic, Inc. has experienced a significant increase in stock performance, outperforming the S&P 500 in recent trading. Despite facing longer-term challenges, the company demonstrates strong management efficiency with a notable return on equity and low debt levels, indicating solid financial health in a competitive market.
Is Hologic, Inc. technically bullish or bearish?
As of May 27, 2025, Hologic, Inc. shows a mildly bearish trend with daily moving averages indicating bearishness, while weekly indicators suggest mild bullishness, but overall performance remains weak compared to the S&P 500.
Is Hologic, Inc. overvalued or undervalued?
As of February 5, 2025, Hologic, Inc. is fairly valued with a P/E ratio of 21, an EV to EBITDA of 14.41, and a ROE of 17.54%, aligning closely with industry peers despite a recent stock performance lag compared to the S&P 500.
Who are in the management team of Hologic, Inc.?
As of March 2022, Hologic, Inc. is led by Mr. Stephen MacMillan as Chairman, President, and CEO, with Ms. Sally Crawford serving as Lead Independent Director and a diverse board of independent directors.
What does Hologic, Inc. do?
Hologic, Inc. is a mid-cap company specializing in diagnostics, medical imaging, and surgical products focused on women's health. As of March 2025, it reported net sales of $1,005 million and a net profit of -$17 million, with a market cap of $17.09 billion.
How big is Hologic, Inc.?
As of Jun 18, Hologic, Inc. has a market capitalization of $17.09 billion, with net sales of $4.03 billion and a net profit of $556.7 million over the latest four quarters.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
